Bayer-backed Boundless Bio (BOLD), an oncology drug developer, has set terms for a proposed $100M initial public offering. In its latest SEC filing, Boundless said it is looking at offering 6.25M ...

Bayer has bolstered its cell and gene therapy platform by securing access to a CRISPR-based gene-editing platform developed by US biotech Mammoth Biosciences. The German group is paying $40 ...